1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCareer development award for early-stage clinician-investigators to advance leadership and research in aging and aging-related diseases.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U. S. citizen or permanent resident early-stage clinician-scientists (primarily physicians) who have secured independent research support and shown leadership potential in aging research. Confirm the full requirements in the official notice before applying.
The current listing shows up to $225,000 per year in direct costs (up to 5 years). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76) are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76) is funded by National Institute on Aging. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Seven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read articleARPA-H awarded $144M across 7 research teams to run the first clinical trials treating aging as a condition — not a disease. How PROSPR reshapes longevity funding and what grant seekers in biotech, academia, and health tech should know.
Read article